神经元特异性烯醇化酶在弥漫大B细胞淋巴瘤缓解患者血清中的表达及其意义

Expression of neuron specific enolase in serum of remission patients with diffuse large B-cell lymphoma and its significance

目的 探讨神经元特异性烯醇化酶（NSE）在弥漫大B细胞淋巴瘤（DLBCL）缓解患者中的表达情况及其与预后的关系.方法 采用电化学发光法检测40例初次诊断后经6～8个疗程化疗达到缓解的DLBCL患者及20例对照组血清NSE水平,分析NSE表达与预后的关系.结果 DLBCL缓解患者NSE表达阳性率为50％（20/40）,对照组NSE表达阳性率为10％（2/10）,两组间比较差异有统计学意义（P＜ 0.001）；NSE表达阴性及NSE表达阳性DLBCL缓解患者2年无进展生存（PFS）率分别为20.9％和6.6％,两组间差异有统计学意义（P＜0.01）；NSE为预后不良独立危险因素.结论 NSE是DLBCL缓解患者的独立不良预后指标,对判断缓解DLBCL的预后有重要意义.

Objective To examine the expression of neuron-specific enolase （NSE） in patients with remission diffuse large B-cell lymphoma （DLBCL）, and to explone its prognostic value. Methods Serum NSE values were mesured by electmchemilumineseence immunoassay in 20 health donors and 40 DLBCL patients reached remission after 6-8 cycles of chemotherapy after initial diagnosis. Results Positive expressions rate of NSE in remission DLBCL patients was 50 %, and was 10 % in health donors （P 〈 0.01）. In remission DLBCL patients, there was significant difference in the 2-year PFS rate between in NSE-positive group and negative group （6.6 % vs 20.9% , P 〈 0.001）. Serum NSE was an independent poor prognostic factor in remission DLBCL patients. Conclusion Serum NSE expressions is an independent poor prognostic factor of remission DLBCL and has significant clinical value.